Delivering for both pharmaceutical and biotech companies. Our portfolio consists of over +75 challenge studies.
Specialists in First-in-Human (FiH) clinical trials, CRS delivers fast, EMA-compliant early-phase drug development services with expert subject recruitment, PK/PD analysis, and dose escalation support.
World leading CRO in infectious and respiratory human challenge trials, offering over 14 validated models, state of the art labs & rapid recruitment.
Phase II–III infectious, respiratory, and cardiometabolic clinical trials across UK and Germany, with expert-led design, rapid recruitment, and advanced diagnostic capabilities.
Abstract
A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a nonrandomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
Read InsightIndustry leader in virology and immunology laboratory services.
Abstract
A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a nonrandomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
Read InsightWorld-class in-patient clinical trial sites across the UK and Germany, offering over 150 beds for early-phase, infectious disease, and specialist studies including advanced quarantine, PK/PD, and biosafety capabilities.
Five integrated outpatient clinical trial sites across the UK and Germany, offering over 1,000 weekly participant screenings, on-site IMP administration, and advanced laboratory capabilities.
Abstract
A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a nonrandomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
Read InsightReliable clinical trial recruitment with over 400,000 volunteers, advanced CRM technology, and tailored participant matching to accelerate your study success.
A short and sharp sentence about how hVIVO help in this service
A short and sharp sentence about how hVIVO help in this service
Expert regulatory affairs support for seamless drug development, from submission preparation to ongoing trial compliance and final reporting.
Accurate, compliant medical writing for clinical, regulatory, and safety documents - tailored to your needs.
Data Management and Biostatistics
Comprehensive data management and biostatistics support for clinical trials, ensuring accurate data capture, analysis, and timely, high-quality study results.
Abstract
A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a nonrandomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
Read InsightExpert CMC support to ensure safe, consistent, and regulatory-ready drug development from concept to market.
Advancing drug candidates with tailored, expertly managed non-clinical development strategies.
Optimising clinical development through expert PK/PD analysis and strategic insight across all phases.
Expert regulatory affairs support for seamless drug development, from submission preparation to ongoing trial compliance and final reporting.
A short and sharp sentence about how hVIVO help in this service
Abstract
A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a nonrandomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
Read Insight
Driving innovation in infectious disease clinical trials through expert study design, rapid recruitment, and scientifically rigorous execution.
Driving innovation in cardiometabolic research with deep expertise, advanced diagnostics, and end-to-end clinical support.
Advancing respiratory health through expertly designed trials, specialist assessments, and targeted patient recruitment.
Expertly designed early-phase trials in renal and hepatic impairment to ensure safe, effective therapies for patients with compromised organ function.
Accelerating dermatology innovation through expert-led studies, advanced assessments, and rapid patient recruitment.
Abstract
A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a nonrandomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
Read MoreAbstract
A phase I dose escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumors
Read MoreAbstract
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study
Read MoreKeep up to date with hVIVO's regulatory news by email alerts.
Keep up to date with hVIVO's regulatory news by email alerts.
Keep up to date with hVIVO's regulatory news by email alerts.
Keep up to date with hVIVO's regulatory news by email alerts.
Keep up to date with hVIVO's regulatory news by email alerts.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna.
